Harrison F. Dillon is a co-founder and President of Solazyme. Prior to founding Solazyme, Dr. Dillon was an associate at Kilpatrick Townsend & Stockton LLP formerly Townsend and Crew LLP, a law firm, from 2003 to 2004. Prior to joining Kilpatrick Townsend & Stockton LLP, Dr. Dillon held a variety of positions related to intellectual property law and technology licensing at Parsons, Behle, and Latimer PLC, a law firm, and the University of Utah Research Foundation, an academic institution. Dr. Dillon obtained a J.D. from Duke University School of Law and a Ph.D. in genetics from the University of Utah. He has served as a member of our board of directors since inception. Dr. Dillon is a valuable member of the board of directors due to his leadership, his extensive knowledge of intellectual property and his extensive understanding of the company, which brings historic knowledge and continuity to the board of directors.
Our board of directors currently consists of eight members, comprised of six non-employee members and our president and chief executive officer. Each director serves until the next meeting of stockholders and until their successors are duly elected and qualified. Mr. Fiddler serves as the Chairman of the board of directors.
Our board of directors is divided into three classes, as follows:
- Class I, which will consist of Ian T. Clark, William D. Lese and Daniel H. Miller whose terms will expire at our annual meeting of stockholders to be held in 2012;
- Class II, which will consist of Michael V. Arbige, Jerry Fiddler and Ann Mather whose terms will expire at our annual meeting of stockholders to be held in 2013; and
- Class III, which will consist of Jonathan S. Wolfson and Harrison F. Dillon whose terms will expire at our annual meeting of stockholders to be held in 2014.